Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 8.2% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics (NTLA) is a biotechnology company specializing in CRISPR/Cas9-based therapies for genetic diseases. The company has been advancing well in its clinical trials and research endeavors.

Why is Intellia Therapeutics, Inc. going up?

NTLA stock is up 8.2% on May 27, 2026 14:47

• NTLA reported a reduced first-quarter loss, demonstrating improved financial performance compared to the prior year. This improvement has likely contributed to the positive movement in the stock.
• Positive Phase 3 clinical data for lonvo-z in Hereditary Angioedema (HAE) and advancements in other trials have enhanced investor confidence in the company's future prospects, leading to increased interest and a favorable market sentiment.
• Analysts have set a fair value target of $26.70 for the company, suggesting potential undervaluation. This, along with the anticipation of new product launches and a strengthened financial position, likely plays a role in the stock's upward momentum.
• The resolution of the patent infringement lawsuit counterclaims signals the end of legal uncertainties, potentially eliminating a source of concern for investors and further supporting the stock's positive trajectory.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

A Look At Intellia Therapeutics (NTLA) Valuation After Narrower First Quarter Loss

Intellia Therapeutics (NTLA) reported a narrower first-quarter net loss of US$96.23 million, with a basic loss per share of US$0.81, showing improvement from the previous year. Despite recent short-term share price declines, the company has seen strong year-to-date and one-year returns, suggesting growing investor interest. Analysts target a fair value of $26.70, indicating the stock may be undervalued, although its high P/S ratio signals potential valuation risks for a loss-making company.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/a-look-at-intellia-therapeutics-ntla-valuation-after-narrowe

A Look At Intellia Therapeutics (NTLA) Valuation After Narrower First Quarter Loss

Intellia Therapeutics reported a narrower first-quarter loss and a basic loss per share of US$0.81, showing an improvement from the previous year. Despite recent short-term share price declines, the company has seen significant year-to-date and one-year returns, leading to a "52.8% Undervalued" narrative. The article discusses whether the market is fully pricing in future growth given the improving financials and analyst targets above the current share price, while also highlighting risks such as high R&D costs and lack of commercial revenue.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/a-look-at-intellia-therapeutics-ntla-valuation-after-narrowe/amp

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

Intellia Therapeutics reported its first quarter 2026 financial results and provided business updates, highlighting successful Phase 3 HAELO clinical data for lonvo-z in Hereditary Angioedema (HAE), leading to a rolling BLA submission and anticipated U.S. launch in early 2027. The company also resumed patient screening for its Phase 3 trials of nex-z in ATTR amyloidosis and strengthened its financial position, expecting existing cash to fund operations into 2028.

https://investingnews.com/intellia-therapeutics-announces-first-quarter-2026-financial-results-and-business-updates/

Intellia Dismisses Four Counterclaims in BlueAllele Patent Suit

Intellia Therapeutics Inc. has dismissed four counterclaims, including one regarding patent inventorship and claims of tortious interference and unfair trade practices, in BlueAllele Corp.'s gene-editing patent infringement lawsuit. This follows a previous dismissal of Intellia's unjust enrichment counterclaim. The dismissals were granted with prejudice by Judge John F. Murphy in the US District Court for the District of Delaware.

https://news.bloomberglaw.com/ip-law/intellia-dismisses-four-counterclaims-in-blueallele-patent-suit

Trending Today

Intellia Therapeutics, Inc. Price History

18.04.2026 - NTLA Stock was down 5.7%

• The recent bearish movement in NTLA stock could be linked to negative insider sentiment, with an increase in share sales by corporate insiders over the past quarter, as noted by a Hold rating and $12.00 price target.
• Despite positive Phase 3 results for lonvo-z and progress on its biologics license application, mixed short-term share price performance and diverse views from analysts may have contributed to the downward pressure on the stock.
• The wide spread in analyst valuations, hinting at uncertainty about the company's growth potential, could have also influenced investors to take a cautious stance, resulting in the bearish movement in NTLA stock.
• In general, while the company's clinical advancements and financial strategy are respected, lingering concerns about valuation and differing views on future growth prospects appear to have impacted the stock performance.

14.04.2026 - NTLA Stock was down 9.8%

• Despite a reduced loss per share in Q1 2026, Intellia Therapeutics (NTLA) witnessed a decline in the market today.
• The company outperformed in earnings but fell short of revenue expectations, potentially influencing negative investor reactions.
• Analysts hold varying perspectives on the company's future, citing worries about sustained losses and the path to profitability that could have impacted the stock price.
• Negative insider sentiment and larger-than-anticipated losses per share in the recent quarter may have contributed to the stock's downturn, notwithstanding optimistic pipeline developments.

14.04.2026 - NTLA Stock was down 5.8%

• NTLA posted a Q1 2026 net loss of $96.2 million, which has sparked worries about its path to profitability and prompted a cautious response from investors.
• While exceeding earnings per share projections, the company fell short on revenue, reporting $15 million, leading to a downward trend in the market.
• The persistent losses, high price-to-sales ratio, and risks of dilution may have contributed to the prevailing bearish sentiment and decline in NTLA shares.
• Despite positive developments in its pipeline, such as successful Phase 3 outcomes for lonvo-z and the lifting of FDA clinical holds for nex-z trials, concerns about financial performance and short-term profitability seem to overshadow these advancements.

01.04.2026 - NTLA Stock was down 5.4%

• Despite successfully raising funds through a public equity offering and filing a Biologics License Application for lonvoguran ziclumeran (lonvo-z) after meeting Phase 3 endpoints, Intellia Therapeutics stock exhibited a bearish trend.
• The market reaction might be linked to investors resorting to profit-taking after having anticipated positive trial results and witnessing a subsequent sell-off as the news had already been factored into the stock price.
• Investor skepticism regarding the commercial potential of lonvo-z in comparison to existing effective therapies may have also influenced the downward movement, as concerns about future revenue generation linger.
• The surge in NTLA shares during pre-market trading following favorable late-stage trial data for lonvo-z possibly led to an overbought situation, causing a correction as traders capitalized on profits, ultimately resulting in the observed bearish movement today.

19.04.2026 - NTLA Stock was down 8.3%

• The recent bearish movement in NTLA's stock may be linked to investor concerns about potential dilution following a recent $180 million equity offering, despite an improved net loss reported in Q1 2026.
• Investors are wary of the possibility of further dilution if current cash burn rates persist, despite Intellia Therapeutics' affirmation of a multi-year cash runway and positive developments in its gene-editing pipeline.
• Market sentiment seems influenced by uncertainties surrounding future funding requirements and the trade-off between benefits from capital raising and risks of dilution, as suggested in recent discussions on the company's valuation and financial performance.
• Despite encouraging results from clinical trials and advancements in regulatory milestones, today's downward movement in the stock price may reflect a broader market reassessment of Intellia Therapeutics' growth prospects and valuation, resulting in a temporary decline in share value.

13.04.2026 - NTLA Stock was up 5.4%

• Despite reporting a significant Q1 loss, Intellia Therapeutics (NTLA) experienced a strong bullish movement in the stock market.
• The bullish movement can be attributed to the company's positive Phase 3 results for lonvo-z in hereditary angioedema (HAE) and the initiation of a rolling BLA submission for a potential U.S. launch in early 2027.
• Investors seem optimistic about Intellia's pipeline progress, including the lifting of FDA clinical holds for nex-z trials in ATTR amyloidosis, which indicates a promising future for the company's gene-editing programs.
• The market may also be reacting positively to Intellia's strategic reductions in R&D spending to focus on lead programs and commercial readiness, signaling a more efficient use of resources for future growth.

27.04.2026 - NTLA Stock was up 8.2%

• NTLA reported a reduced first-quarter loss, demonstrating improved financial performance compared to the prior year. This improvement has likely contributed to the positive movement in the stock.
• Positive Phase 3 clinical data for lonvo-z in Hereditary Angioedema (HAE) and advancements in other trials have enhanced investor confidence in the company's future prospects, leading to increased interest and a favorable market sentiment.
• Analysts have set a fair value target of $26.70 for the company, suggesting potential undervaluation. This, along with the anticipation of new product launches and a strengthened financial position, likely plays a role in the stock's upward momentum.
• The resolution of the patent infringement lawsuit counterclaims signals the end of legal uncertainties, potentially eliminating a source of concern for investors and further supporting the stock's positive trajectory.

22.04.2026 - NTLA Stock was up 5.6%

• The dismissal of four counterclaims in the BlueAllele patent infringement lawsuit is seen as a positive development for Intellia Therapeutics, reducing legal uncertainties and potential financial liabilities.
• The submission of the CRISPR-based gene editing therapy, nex-z, poses a unique regulatory challenge for the FDA, highlighting the innovative nature of Intellia's technology and its potential market impact.
• Despite concerns about dilution from a recent equity offering, Intellia's improved net loss in Q1 2026 and emphasis on a multi-year cash runway are reassuring investors about the company's financial stability and ability to execute its gene-editing pipeline.
• Investor focus on Intellia's gene-editing pipeline progress, upcoming clinical trial readouts, and regulatory milestones underscores the market's anticipation of potential breakthroughs in the competitive gene-editing landscape, further boosting confidence in the company's growth prospects.

30.03.2026 - NTLA Stock was up 10.8%

• NTLA's stock surged after announcing the pricing of a public offering, raising significant gross proceeds and indicating investor confidence in the company's future prospects.
• The successful results of the Phase 3 trial for lonvo-z, Intellia's gene-editing medicine for hereditary angioedema (HAE), played a crucial role in driving up the stock price.
• The initiation of a rolling Biologics License Application submission to the FDA and the anticipation of a potential U.S. launch in the first half of 2027 further fueled positive investor sentiment.
• Overall, the combination of successful trial data, regulatory progress, and strong financial backing contributed to NTLA's bullish market movement today.

11.04.2026 - NTLA Stock was up 5.0%

• The bullish movement in NTLA's stock price can be attributed to the positive anticipation of beating earnings estimates, supported by a history of surpassing EPS estimates in previous quarters.
• The announcement of Intellia's participation in multiple investor conferences and fireside chats may have increased investor confidence in the company's strategic initiatives and future prospects.
• Cathie Wood's ARK Invest increasing its stake in NTLA could have also contributed to the bullish momentum, signaling confidence from a prominent investor in the biotech sector.
• Conflicting valuation metrics may have caused some volatility in the stock price, with investors potentially weighing the undervaluation suggested by the DCF model against the overvaluation indicated by the P/S ratio.

08.04.2026 - NTLA Stock was up 5.9%

• NTLA is expected to beat earnings estimates, with a positive Earnings ESP and a history of surpassing EPS estimates, indicating strong financial performance.
• A major investment firm increased its stake in NTLA, showcasing confidence in the company's future prospects and contributing to positive market sentiment.
• The announcement of NTLA's participation in upcoming investor conferences and positive Phase 3 results for its CRISPR gene editing therapy likely generated excitement among investors, driving the bullish movement in the stock.
• Overall, the combination of favorable financial outlook, increased institutional interest, and positive developments in its therapeutic pipeline propelled NTLA's stock price higher today.

12.04.2026 - NTLA Stock was down 7.0%

• NTLA stock's decline might be linked to the company's Q1 2026 financial figures, indicating a net loss of $96.2 million and lower revenue compared to the previous year.
• Despite achieving Phase 3 milestones for lonvo-z and progressing its gene-editing projects, investors possibly worried about NTLA's financial performance and the recent stock offering for additional funding.
• The difference in valuation assessments, with the DCF model suggesting undervaluation and the P/S ratio hinting at overvaluation, may have contributed to investor uncertainty, influencing the bearish movement.
• Overall, investor sentiment towards NTLA appears guarded today, considering the promise of its gene editing treatments alongside the company's financial struggles and valuation ambiguity.